← Leaderboards
David Michael Markovitz
University Of Michigan At Ann Arbor
$15,697,771
Attributed
$16,908,287
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,908,287 · 9
By mechanism
R01$16,153,599 · 7
R21$754,688 · 2
Top collaborators
- Hal E. Broxmeyer4 shared
- Hashim M Al-Hashimi2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Robert M Strieter$9,675,893
- Jonathan S Bromberg$26,279,150
- Peter A Ward$11,493,015
- Steven Lynn Kunkel$20,708,735
- Daniel G. Remick$12,614,334
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularIn VivoProteinsCellsLinkOncogenesPathogenesisIn VitroInhibitor/AntagonistBiologyMediatingPublic Health RelevanceBloodMalignant NeoplasmsLaboratoriesResearch PersonnelAutoimmunityAutoimmune DiseasesMonocyteLeadGene ExpressionLifeMacrophageSafety
Grant awards (33)
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses$714,193
R01 · FY2025 · AI · contact PI
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses$714,193
R01 · FY2024 · AI · contact PI
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses$728,193
R01 · FY2023 · AI · contact PI
DEK Regulation of Hematopoietic Stem Cell Renewal, Fate, and Hematopoiesis$499,587
R01 · FY2019 · DK
DEK Regulation of Hematopoietic Stem Cell Renewal, Fate, and Hematopoiesis$499,043
R01 · FY2018 · DK
DEK Regulation of Hematopoietic Stem Cell Renewal, Fate, and Hematopoiesis$498,986
R01 · FY2017 · DK
DEK Regulation of Hematopoietic Stem Cell Renewal, Fate, and Hematopoiesis$512,978
R01 · FY2016 · DK
Replication of Human Endogenous Retroviruses in Modern Humans$1,147,314
R01 · FY2013 · CA · contact PI
Biological Activity of Lead Compounds Targeting HIV-1 TAR RNA$179,942
R21 · FY2013 · AI · contact PI
Replication of Human Endogenous Retroviruses in Modern Humans$1,231,806
R01 · FY2012 · CA · contact PI
DEK and TNF inhibitors in juvenile arthritis$378,564
R01 · FY2012 · AI · contact PI
Biological Activity of Lead Compounds Targeting HIV-1 TAR RNA$230,496
R21 · FY2012 · AI
Replication of Human Endogenous Retroviruses in Modern Humans$82,609
R01 · FY2012 · CA · contact PI
Replication of Human Endogenous Retroviruses in Modern Humans$1,240,230
R01 · FY2011 · CA · contact PI
DEK and TNF inhibitors in juvenile arthritis$378,564
R01 · FY2011 · AI · contact PI
Replication of Human Endogenous Retroviruses in Modern Humans$1,287,518
R01 · FY2010 · CA · contact PI
DEK and TNF inhibitors in juvenile arthritis$382,388
R01 · FY2010 · AI · contact PI
Replication of Human Endogenous Retroviruses in Modern Humans$1,435,274
R01 · FY2009 · CA · contact PI
DEK and TNF inhibitors in juvenile arthritis$386,250
R01 · FY2009 · AI · contact PI
CXC Chemokines and HIV Pathogenesis$355,788
R01 · FY2009 · AI · contact PI
CXC Chemokines and HIV Pathogenesis$355,788
R01 · FY2008 · AI · contact PI
CXC Chemokines and HIV Pathogenesis$362,679
R01 · FY2007 · AI · contact PI
CXC Chemokines and HIV Pathogenesis$373,511
R01 · FY2006 · AI · contact PI
C-X-C Chemokines and Kaposi's Sarcoma$292,820
R01 · FY2005 · HL
CXC Chemokines and HIV Pathogenesis$181,688
R01 · FY2005 · AI
CXC Chemokines and HIV Pathogenesis$344,250
R21 · FY2004 · AI
C-X-C Chemokines and Kaposi's Sarcoma$292,820
R01 · FY2004 · HL
C-X-C Chemokines and Kaposi's Sarcoma$292,820
R01 · FY2003 · HL
REGULATION OF HIV2 TRANSCRIPTION AND REPLICATION$318,986
R01 · FY2002 · AI
C-X-C Chemokines and Kaposi's Sarcoma$296,390
R01 · FY2002 · HL
REGULATION OF HIV2 TRANSCRIPTION AND REPLICATION$309,695
R01 · FY2001 · AI
C-X-C Chemokines and Kaposi's Sarcoma$302,250
R01 · FY2001 · HL
REGULATION OF HIV2 TRANSCRIPTION AND REPLICATION$300,674
R01 · FY2000 · AI